Pediatric Cardiology News

Treatment with immune globulin led to left ventricular systolic function recovery in children with acute cardiac decompensation from inflammation associated with COVID-19, according to a study published in Circulation.

Dexrazoxane appeared to preserve cardiac function without compromising EFS and OS among pediatric patients undergoing chemotherapy for acute myeloid leukemia, according to results of a prospective study published in Journal of Clinical Oncology.

A scientific statement from the American Heart Association addressed the role of caregivers in the development of healthy eating behaviors in children, actions that can be taken by caregivers to improve these outcomes and challenges that may inhibit these changes.

Patients with elevated systolic BP, type 2 diabetes and obesity in early life had an accelerated progression of risk factors associated with early vascular aging, according to a study published in the Journal of the American Heart Association.

Kawasaki disease was first characterized in the late 1960s and was previously called “mucocutaneous lymph node disease.” Recently, hospitals in several countries have reported children with Kawasaki-like symptoms possibly associated with COVID-19. We have seen a few cases at my hospital, and they can be quite challenging.

Social deprivation and environmental pollutant exposure are potential risk factors for live-born congenital heart disease in California, indicating that harmful toxins may be prevalent in at-risk communities, researchers reported.

A draft recommendation from the U.S. Preventive Services Task Force stated there is insufficient evidence of benefits or harms to support screening for high BP in asymptomatic children and adolescents.

Individuals who began smoking at a younger age were more likely to be daily smokers as adults and less likely to have quit smoking by their 40s, according to findings from the International Childhood Cardiovascular Cohort published in the Journal of the American Heart Association.

CHF Solutions announced the FDA cleared its ultrafiltration device for the treatment of hypervolemia in adults and pediatric patients who weigh 20 kg or more.

The risk for congenital heart disease-related infant mortality was higher when mothers lived farther from specialized pediatric cardiac centers, according to a research letter published in Circulation.